Brightline Diagnostics builds profile and involvement within UK’s in vitro diagnostics sector as a new BIVDA Full Corporate Member
Brightline Diagnostics (DX), a joint venture formed by Stream Bio and Chelsea Technologies combining novel technologies to create a unique platform for a wide range of diagnostic targets, is delighted to announce that it has become a Full Corporate Member of the British In Vitro Diagnostics Association (BIVDA).
This announcement represents another significant step forward for the company, establishing a more prominent profile and policymaking involvement within the UK’s in vitro diagnostics (IVD) sector. The benefits of BIVDA membership include invaluable networking opportunities, crucial early industrial insight and participation in a range of working parties and special interest groups.
BIVDA is the national association for manufacturers and distributors of IVD products in the UK, representing over 160 members ranging from British start-up companies to multinational corporations. Through collaboration with its stakeholders, BIVDA aims to ensure that IVD technology can not only enhance the diagnosis of conditions but also the prevention and treatment of disease.
BIVDA offers three different types of membership: Full, Associate and Overseas. In the UK, Brightline DX has successfully qualified as a BIVDA Full Corporate Member. This type of membership ensures Brightline DX’s involvement and voting right within BIVDA, allowing it to contribute to the voice of the industry in key discussions with policymakers, media and relevant stakeholders across the UK and EU.
Brightline DX’s Claritas diagnostic system, with applications under development in rapid point-of-care diagnostics, incorporates Stream Bio’s innovative Conjugated Polymer Nanoparticles (CPNs™) coupled with Chelsea Technologies’ novel fluorescent highly sensitive reader. Full Corporate Membership at BIVDA will further strengthen and improve recognition of Brightline DX’s capabilities and potentially facilitate collaborative partnerships with other fellow BIVDA members.
Andy Chaloner, Director at Brightline DX, said: “We are proud to be a member of BIVDA and look forward to collaborating with other members to advance the IVD industry in the UK. This membership will help us to develop our technology and realise Brightline DX’s potential to improve efficiency and reduce costs associated with healthcare, ultimately improving patient outcomes.”